Intranasal oxytocin simultaneously calmed the brain's fear center and boosted the rational control center, accelerating fear extinction in a controlled human experiment.
Dual-actionOxytocin simultaneously suppressed amygdala (fear) activity and enhanced prefrontal cortex (control) signaling — the exact combination neuroscience models predict would optimize fear extinction
What the researchers found
Intranasal oxytocin (24 IU) administered after Pavlovian fear conditioning facilitated fear extinction in healthy men. Using fMRI, researchers showed that oxytocin simultaneously dampened amygdala activity (the brain's fear center) while boosting prefrontal cortex signaling (the region responsible for rational control over fear). This dual action matches exactly what neuroscience models predict would be needed to overcome conditioned fear responses.
Specifically, in the early phase of extinction, oxytocin increased skin conductance responses and prefrontal cortex activation to conditioned fear stimuli. In the late phase, oxytocin enhanced the decline of fear responses. The amygdala suppression was present in both phases, suggesting a sustained calming effect on the brain's alarm system.
Why it matters
Fear extinction — learning that something previously threatening is now safe — is the core mechanism behind exposure therapy for anxiety disorders and PTSD. Many patients struggle with extinction because their amygdala remains overactive while their prefrontal cortex can't provide enough inhibitory control. This study shows that oxytocin addresses both problems simultaneously, making it a potential pharmacological enhancer for exposure therapy. A nasal spray given before therapy sessions could make treatment significantly more effective.
The numbers in context
n=62 · healthy males · 24 IU intranasal oxytocin · double-blind, placebo-controlled · fMRI + skin conductance · amygdala suppressed + prefrontal cortex enhanced · accelerated extinction in late phase
How the study worked
Randomized, double-blind, parallel-group, placebo-controlled fMRI study with 62 healthy male participants. Subjects underwent Pavlovian fear conditioning, then received either intranasal oxytocin (24 IU) or placebo before extinction training. Brain activity was measured via functional magnetic resonance imaging, and skin conductance (electrodermal) responses served as a physiological measure of fear. Both early and late phases of extinction were analyzed separately.
Who was studied
62 healthy adult males
What this study cannot tell us
Only healthy male participants were studied — results may not generalize to women or to clinical populations with anxiety disorders or PTSD. The Pavlovian fear conditioning paradigm in a lab setting is a simplified model of real-world traumatic fear. The study tested a single dose of oxytocin in a single session; repeated dosing effects are unknown. Intranasal oxytocin's exact pathway to the brain remains debated. The study measured fear extinction but not long-term fear memory or return of fear.
How to read the evidence
This is a well-designed, double-blind, placebo-controlled RCT with functional neuroimaging published in Biological Psychiatry — a top-tier psychiatric journal. The 'Strong' grade reflects the rigorous design, objective brain imaging outcomes, and the 62-participant sample size appropriate for an fMRI study.
When this study was published
Published in 2015, this study remains influential in the oxytocin-extinction literature. Subsequent research has continued to explore oxytocin as an adjunct to exposure therapy, with some clinical trials in PTSD populations ongoing.
The bigger picture
Exposure therapy is the gold standard for treating PTSD and anxiety disorders, but many patients don't respond because their brains struggle to form new, safe associations over traumatic ones. Pharmacologically enhancing extinction learning — essentially helping the brain rewrite fear memories — is one of the most actively pursued strategies in psychiatry. This study provides neuroscientific evidence that oxytocin hits the right brain targets to serve as an extinction enhancer, joining a small group of candidates (including MDMA and D-cycloserine) being studied for this purpose.
Questions still open
- Does oxytocin enhance fear extinction in people with actual PTSD or anxiety disorders, not just healthy volunteers?
- Would repeated oxytocin dosing before multiple therapy sessions produce cumulative benefits?
- Does oxytocin work the same way in women, given known sex differences in oxytocin receptor expression?
Common questions
How could oxytocin help with anxiety therapy?
Is oxytocin nasal spray available for anxiety treatment?
Read the original research
Oxytocin facilitates the extinction of conditioned fear in humans.
Biological psychiatry, 78(3), 194-202
Citation
Eckstein, Monika; Becker, Benjamin; Scheele, Dirk; Scholz, Claudia; Preckel, Katrin; Schlaepfer, Thomas E; Grinevich, Valery; Kendrick, Keith M; Maier, Wolfgang; Hurlemann, René. (2015). Oxytocin facilitates the extinction of conditioned fear in humans.. Biological psychiatry, 78(3), 194-202. https://doi.org/10.1016/j.biopsych.2014.10.015